second-generation oncolytic VSV therapy expressing IFN-beta (Vyriad)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namesecond-generation oncolytic VSV therapy expressing IFN-beta (Vyriad)
Drug Alias Namesecond-generation VSV (Omnis Pharma)
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusN/A
Highest Status in ChinaN/A
Originator CompaniesOmnis Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOmnis Pharma IncVyriad
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A